Soluble complement receptor 1 (sCR1) is not as effective as cobra venom factor in the treatment of experimental allergic neuritis

References

• Candinas, D., Lesnikoski, B. A., Robson, S. C, Miyatake, T„ Scesney, S. M., Marsh, H. C, Ryan, U. S., Dalmao, A. P., Hancock, W. W. & Bach, F. H. (1996). “Effect of repetitive high-dose treatment with soluble complement receptor type 1 and Cobra Venom Factor on discordant xenograft survival,” Transplantation, 62, 336–342.
   Google Scholar
• Chavez-Cartaya, R. E., Pino DeSola, G., Wright, L., Jamieson, N. V. & White, D. J. G. (1995). “Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion,” Transplantation, 59, 1047–1052.
   PubMed Web of Science ®Google Scholar
• Couser, W. G., Johnson, R. J., Young, B. A., Yen, C. G., Toth, C. A. & Rudolph, A. R. (1995). ‘The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis,” Journal of the American Society of Nephrology, 5, 1888–1894.
   Google Scholar
• Dashill, S„ Vanguri, P. & Koski, C. L. (1994). “Cytokines and cyclic AMP induce C3 production in rat Schwann cells,” Journal of Immunology, 150, part II. 225A.
   Web of Science ®Google Scholar
• Dianzani. U. & Malavasi, F. (1995). “Lymphocyte adhesion to endothelium,” Critical Reviews in Immunology, 15,167-300.
   Web of Science ®Google Scholar
• Fcasby, T. E. Gilbert, J. J., Hahn, A. F. & Neilson, M. (1987). “Complement depletion suppresses
   Google Scholar
• Lewis rat experimental allergic neuritis,” Brain Research, 419, 97–103.
   Google Scholar
• Hafer-Macko, C. E., Sheikh, K. A., Li, C. Y., Ho, T. W., Comblath, D. R., McKhann, G. M., Asbury, A. K. & Griffin, J. W. (1996). “Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy,” Annals of Neurology, 39, 625–635.
   PubMed Web of Science ®Google Scholar
• Hahn, A. F., Feasby, T. E., Wilkie, L. & Lovgren, D. S. (1991). “P2-peptide induced experimental allergic neuritis: a model to study axonal degeneration.’Mcta Neuropathologica, 82, 60–65.
   Google Scholar
• Hartung, H. P., Schwenke, C, Bilter-Suermann, D. & Toyka, K. V. (1987). “Guillain-Barre syndrome: activated complement components C3a and C5a in CSF,” Neurology, 37, 1006–1009.
   Google Scholar
• Hartung, H. P., Stoll, G. & Toyka, K. V. (1993) Immune reactions in the peripheral nervous system In: Dyck, P.J. & Thomas, P. K., (eds.) Peripheral Neuropathy, (Philadelphia, Saunders), pp. 418–444.
   Google Scholar
• Hill, J., Lindsay, T. F, Ortiz, F, Yeh, C. G., Hechtman, H. B. & Moore, F. D., Jr., (1992). “Soluble complement receptor type I ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the ral,” Journal of Immunology, 149, 1723–1728.
   Google Scholar
• Jung, S-, Toyka, K. V. & Hartung, H. P. (1995). “Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats.” Neuroscience Letters, 200, 167–170.
   PubMed Web of Science ®Google Scholar
• Koski, C. L., Humphrey, R. & Shin, M. L. (1985). “Anti-peripheral myelin antibody in patients wilh demyelinating neuropathy: Quantitative and kinetic determination of serum antibody by complement component 1 fixation,” Procedings of the National Academy of Science USA, 82,905-910.
   Google Scholar
• Koski, C. L., Sanders, M. E., Swoveland, P. T„ Lawley, T. J., Shin, M. L, Frank, M. M. & Joiner, K. A. (1987). “Activation of terminal components of complement in patients with Guillain-Barre syndrome and other demyelinating neuropathies,” Journal of Clinical Investigation, 80, 1492–1497.
   PubMed Web of Science ®Google Scholar
• McPhaden, A. R. & Whaley, K. (1993). “Complement biosynthesis by mononuclear phagocytes.” Immunology Research, 12, 213–232.
   PubMed Web of Science ®Google Scholar
• Piddlesden, S. J., Storch, M. K., Hibbs, M., Freeman, A. M., Lassmann, H. & Morgan, B. P. (1994). “Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis,” Journal of Immunology, 152,5477-5484.
   Web of Science ®Google Scholar
• Pruitl, S. K., Kirk, A. D., Bollinger, R. R., Marsh, H. C, Jr. Collins, B. H., Levin, J. L., Mault, J. R., Heinle, J. S„ Ibrahim, S. & Rudolph, A. R. (1994). ‘The effect of soluble complement receptor 1 on hyperacute rejection of porcine xenografts,” Transplantation, 57, 363–370.
   Google Scholar
• Sanders, M. E., Koski, C. L., Robbins, D., Shin, M. L., Frank, M. M. & Joiner, K. A. (1986). “Terminal complement pathway activation in cerebrospinal fluid in Guillain-Barre- syndrome and multiple sclerosis,” Journal of Immunology, 136,4456-4459.
   Web of Science ®Google Scholar
• Sawant-Mane, S., Clark, M. B. & Koski, C. L,. (1991). “In vitro demyelination by serum antibody from patients with Guillain-Barr6 syndrome requires terminal complement complexes,” Annals of Neurology, 29, 397–404.
   PubMed Web of Science ®Google Scholar
• Sawant-Mane, S., Piddlesden, S. J., Morgan, B. P., Holera, V. M. & Koski, C. L. (1996). “CD 59 homologue regulates complement dependent cytolysis of rat Schwann cells,” Journal of Neuroimmunology, 69,63-71.
   Web of Science ®Google Scholar
• Stoll, G., Schmidt, B., Jander, S., Toyka, K. V. & Hartung, H. P. (1991). “Presence of the terminal complement complex (C5b-9) precedes myelin degradation in immune-mediated demyelination of the rat peripheral nervous system,” Annals of Neurology, 30, 147–155.
   Google Scholar
• Vaporciyan, A. A., Mulligan, M. S., Warren, J. S., Barton, P. A., Miyasaka, M. & Ward, P. A. (1995). “Up-regulation of lung vascular ICAM-1 in rats is complement dependent,” Journal of Immunology, 155,1442-1449.
   Web of Science ®Google Scholar
• Von Zabern, I. (1993). Effects of venoms of different animal species on the complement system. In: Activators and inhibitors of complement (ed.) R.B. Sim, (Kluwer Academic Publishers, The Netherlands), pp. 127–135.
   Google Scholar
• Vriesendorp, F. J., Flynn, R. E., Pappolla, M. A. & Koski, C. L. (1995). “Complement depletion affects demyelination and inflammation in experimental autoimmune neuritis,” Journal of Neuroimmunology, 58, 157–165.
   PubMed Web of Science ®Google Scholar
• Weisman, H. F., Bartow, T., Leppo, M. K., Marsh, H. C, Carson, G. R., Concino, M. F., Roux, K. H., Weisfeldt, M. L. & Fearon, D. T. (1990). “Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischaemic myocardial inflammation and necrosis,” Science, 249, 146–15.
   Google Scholar